4.7 Review

The future of transcatheter mitral valve interventions: competitive or complementary role of repair vs. replacement?

期刊

EUROPEAN HEART JOURNAL
卷 36, 期 26, 页码 1651-U22

出版社

OXFORD UNIV PRESS
DOI: 10.1093/eurheartj/ehv123

关键词

Transcatheter mitral intervention; Transcatheter mitral repair; Transcatheter mitral implantation

资金

  1. Valtech Cardio
  2. Abbott Vascular
  3. Medtronic
  4. BSC
  5. MValve
  6. Micardia
  7. Edwards
  8. WL Gore
  9. St. Jude
  10. Astra Zeneca
  11. Boston Scientific
  12. Gore
  13. Atritech
  14. AGA Medical
  15. St Jude Medical
  16. Circulite
  17. Coherex
  18. Biosense Webster
  19. Stereotaxis
  20. Cardiofocus
  21. Mitralign
  22. BMDSys
  23. ACT
  24. Maya
  25. Apama
  26. Topera
  27. Recor
  28. Endosense
  29. SynapticMed
  30. CardiacImplants
  31. Biotronik
  32. AGA
  33. AstraZeneca
  34. Bayer
  35. Berlin Chemie
  36. Biotronic
  37. BMS
  38. Boehringer Ingelheim
  39. Daiichi Sankyo
  40. Cordis
  41. Novartis
  42. Pfizer
  43. Sanofi Aventis

向作者/读者索取更多资源

Transcatheter mitral interventions has been developed to address an unmet clinical need and may be an alternative therapeutic option to surgery with the intent to provide symptomatic and prognostic benefit. Beyond MitraClip therapy, alternative repair technologies are being developed to expand the transcatheter intervention armamentarium. Recently, the feasibility of transcatheter mitral valve implantation in native non-calcified valves has been reported in very high-risk patients. Acknowledging the lack of scientific evidence to date, it is difficult to predict what the ultimate future role of transcatheter mitral valve interventions will be. The purpose of the present report is to review the current state-of-the-art of mitral valve intervention, and to identify the potential future scenarios, which might benefit most from the transcatheter repair and replacement devices under development.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据